What The Study Did: This Viewpoint highlights loopholes in U.S. orphan drug policy as exemplified by the use of remdesivir to treat COVID-19.
Authors: Kao-Ping Chua, M.D., Ph.D., of the University of Michigan in Ann Arbor, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2020.2759)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
###
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.2759?guestAccessKey=17d5c228-3e67-46bb-8c1a-212515e164a3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081720
JAMA Internal Medicine